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Summary 
Polyketides are a structurally and functionally diverse family of bioactive natural 
products that have found widespread application as pharmaceuticals, 
agrochemicals and veterinary medicines. In bacteria complex polyketides are 
biosynthesised by giant multifunctional megaenzymes, termed modular 
polyketide synthases (PKSs), which construct their products in a highly 
coordinated assembly line-like fashion from a pool of simple precursor 
substrates. The multifaceted enzymology of PKSs is not only a fascinating target 
for study, but also presents considerable opportunities for the reengineering of 
these systems affording access to functionally optimised unnatural natural 
products.  Here we provide an introductory primer to modular polyketide 
synthase structure and function, and highlight recent advances in the 
characterisation and exploitation of these systems. 
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1. Introduction  
Polyketide natural products are a proven source of high-value bioactive small 
molecules (1). These include compounds that have become mainstays for the 
treatment of human and animal diseases, and others that have found application 
as agrochemicals, flavours, fragrances and nutraceuticals (2, 3). Illustrative 
examples of clinically relevant polyketides include the statin family of cholesterol 
lowering agents, erythromycin A and related macrolide antibiotics, and the anti-
parasitic avermectins, which are used extensively in veterinary medicine (Fig. 1) 
(3–5). The wealth of structural and functional diversity found within the 
polyketides is almost unsurpassed amongst natural products (6). This, coupled 
to their exploitable bioactivities, has made both the compounds themselves, and 
the cellular machineries responsible for their biosynthesis, a source of intrigue 
and fascination for researchers worldwide.  
Polyketides of bacterial origin represent a significant proportion of the natural 
product pool (1). These compounds function to confer evolutionary fitness to the 
producing host, acting as defense agents or signaling molecules (7, 8). 
Commonly, they are biosynthesised through the action of giant multi-functional 
megaenzymes, termed modular polyketide synthases (PKSs), which utilise 
sequential condensation chemistry to construct elaborate product scaffolds from 
simple carboxylic acid substrates (9, 10). This biosynthetic logic permits the 
assembly of a suite of molecules that are in principle of almost unlimited 
chemical diversity. In addition, the highly modular architecture of these systems 
raises intriguing possibilities for their modification and manipulation through 
the addition, removal, or substitution of synthase modules or domains therein 
(11, 12). This approach has been exploited to generate an even larger portfolio of 
useful molecules, the so-called unnatural natural products (13). With the advent 
of synthetic biology and the increasing adoption of the concepts and practices of 
rational design, it is inevitable that synthase reengineering will become more 
reliable and expedient in the future (14, 15). Here we outline the basic principles 
of modular PKS enzymology, highlighting recent developments in the 
characterisation of these systems, and discuss future prospects for harnessing 
their biosynthetic potential. 
 
2. Modular PKSs and the Biosynthetic Process  
Modular PKSs are amongst the largest and most sophisticated enzymes known. 
In extreme cases their proteinogenic mass can exceed 5 MDa. The distinguishing 
structural feature of these systems is their assembly line-like architecture, which 
comprises a series of linearly arranged, multi-domain extension modules, housed 
in sequence within giant polypeptide chains (1, 16). Biosynthesis upon these 
systems proceeds in step-wise fashion, through the processive transfer and 
extension of the nascent polyketide chain, as it progresses from one module to 
the next. Each module within the synthase complex incorporates a single 
carboxylic acid substrate, derived from a pool of simple precursors, into the 
pathway product (Fig. 2) (1, 6, 17, 18) . The first module of the PKS initiates 
biosynthesis through the selection and loading of a starter unit. Each subsequent 
module within the PKS catalyses the thiotemplated addition of a defined 
extender unit to this initial priming substrate. In some cases, however, 
phenomena including module ‘skipping’ or iterative ‘stuttering’ have been 
reported (19, 20). The structures and properties of polyketides biosynthesised 
via this route are dictated by the number, identity, and incorporation order of 
the starter and extender units from which they are assembled. These factors are 
defined by the sequence of the modules that constitute the PKS assembly line. 
For this reason modular PKSs can be considered to possess an inherent 
biosynthetic programming, where synthase nucleotide sequence is co-linearly 
related to product chemistry (21, 22). This relationship provides a powerful tool 
for the prediction and analysis of synthase function, requiring knowledge only of 
PKS gene sequence. In addition, given that the open reading frames (ORFs) that 
encode PKS assembly lines and their associated tailoring enzymes are commonly 
clustered within the genomes of biosynthetically competent microorganisms, 
PKS nucleotide sequences provide a useful analytical tool by which synthase 
components can be readily identified and functionally assigned (23, 24). 
To perform the required set of chemical reactions necessary to extend a 
polyketide chain by a single acyl unit each PKS extension module must minimally 
house three essential domains. These are; an acyltransferase (AT) domain, 
responsible for the selection and loading of carboxylic acid extender units 
derived from their coenzyme-A (CoA) thioesters; an acyl carrier protein (ACP), 
possessing a phosphopantetheine arm, which acts as a site of covalent tethering 
for both the growing product chain and selected extender units; and a 
ketosynthase (KS) domain, which catalyses the carbon-carbon bond forming 
Claisen condensation of the downstream product chain with the upstream ACP 
tethered extender unit (Fig. 2). This minimal KS-AT-ACP module architecture 
may be elaborated to include additional auxiliary domains that further modify 
the incorporated acyl unit. Such modifications may take place at the reactive α-
position or the β-carbonyl. An example of the former is the introduction of an α-
methyl substituent via a reaction catalysed by a C-methyltransferase (CMeT), 
which exploits S-adenosyl methionine as a methyl source (Fig. 2). Alternatively 
the β-carbonyl of the incorporated acyl unit may be reduced in a reaction 
catalysed by a ketoreductase domain (KR) to form a β-hydroxy substituent. This 
may in turn undergo dehydration, catalysed by a dehydratase domain (DH), 
yielding an α/β-unsaturated thioester. Finally an enoyl reductase (ER) may act to 
reduce this species yet further yielding a product fully reduced at the β-position 
(Fig. 2). Both the substrate selectivity of the module embedded AT domain and 
the module’s compliment of auxiliary domains, offer complementary 
mechanisms for achieving diverse product chemistry (1, 6, 17, 18).   
Upon reaching the final module of the PKS assembly line the immature 
polyketide product is liberated from the synthase via cleavage of its covalent 
tether. In the majority of modular PKSs this process is catalysed by a thioesterase 
that forms either the C-terminal domain of the synthase, or functions as a stand-
alone enzyme (25). Frequently, following release from the PKS, the 
biosynthesised product is subjected to additional site-specific tailoring 
modifications catalysed by free-standing enzymes. Tailoring modifications are in 
many cases implicitly required to establish the bioactivity of the synthase 
product. Examples include glycosylation, halogenation, methylation and 
hydroxylation among others (1, 10, 26). 
Modular PKS enzymology is readily distinguishable from that of other polyketide 
synthases. Iteratively acting type I PKSs (iPKSs) found in fungi are smaller but 
inherently more sophisticated systems, which use a single set of functional 
domains to accomplish the biosynthesis of their products, in a manner analogous 
to that of the type I fatty acid synthase (27–30). Uniquely, the domains that 
comprise iPKSs often only catalyse their specific transformations during a sub-
set of chain extension cycles, establishing a defined biosynthetic programme that 
violates the colinearity of synthase sequence and product chemistry. Type II 
PKSs are transiently assembled iteratively acting complexes comprised of 
discrete proteins (31, 32). Consequently type II systems are significantly smaller 
and less intricate than both modular and iteratively acting type I PKSs. 
Biosynthesis upon type II PKSs proceeds in two discernable phases, initiation 
and chain extension, which are catalysed by the minimal type II PKS assembly, 
comprising two KS like condensing enzymes and an ACP. The minimal KS-ACP 
machinery may be further elaborated through the incorporation of a selection of 
additional domains including ketoreductases, cyclases and aromatases. Type III 
PKSs, which are widely distributed amongst bacteria, fungi and plants are in 
essence free standing KS domains that act to catalyse the sequential 
condensation of acetate units to a CoA derived starter unit (33–35). Chemical 
diversity in the products of type III systems arises due to the choice of starter 
unit, the number of chain extension steps catalysed, the mechanism of 
cyclisation, and product modification through the action of allied tailoring 
enzymes. 
 
3. The DEBS Paradigm 
Early attempts to delineate the enzymology of modular PKSs focused on the 
deoxyerythronolide B synthase (DEBS). This system is responsible for the 
biosynthesis of 6-deoxyerythronolide (6-dEB), the macrolide nucleus of the 
clinically relevant antibiotic erythromycin A (4). Studies of DEBS resulted in the 
establishment of many of the central tenets of modular PKS enzymology and as 
such this system serves as a useful test case for illustrating the basic principles of 
PKS function (36). 
DEBS is encoded for by a series of ORFs clustered on the genome of the soil-
dwelling actinomycete Saccharopolyspora erythraea (37). This cluster comprises 
the genes eryAI-III that encode the core biosynthetic machinery of DEBS (DEBS 
1-3), along with a number of associated tailoring and regulatory proteins (Fig. 3) 
(36, 38). DEBS was the first modular PKS gene cluster to be sequenced, thus 
providing initial evidence for the distinctive modular assembly line-like 
architecture of bacterial PKSs (21, 37). This analysis also proved instrumental in 
establishing the co-linear relationship between synthase nucleotide sequence 
and product chemistry.  
Each module within DEBS consists of a discrete set of domains that are 
responsible for the incorporation and reductive tailoring of a designated 
extender unit at a precise location within the growing product chain. Each 
domain is functionally specific and contributes to the incorporation of a single 
extender unit within its host module. Biosynthesis upon DEBS is initiated by a 
loading module, located at the N-terminus of DEBS 1, which consists of an AT, 
nominally selective for a propionate starter unit, and an ACP onto which this unit 
becomes tethered. It has been reported that this initial loading step is more 
promiscuous than was initially presumed and that in addition to propionate, 
non-native extender units can also be accepted by the starter module AT (39–
41).  
The remainder of DEBS comprises 6 extension modules distributed across DEBS 
1-3 and a C-terminal TE domain that catalyses the release and cyclisation of the 
immature PKS product, the 14-membered 6-dEB macrolactone (42). The 
modules within DEBS are numbered in the order in which they act during 
biosynthesis and each houses a single AT, ACP and KS domain. Each of the 
extender module embedded AT domains of DEBS is selective for (2S)-
methylmalonyl-CoA. In addition to their compliment of core domains, modules 1, 
2, 5 and 6 also house active KRs. Consequently, extender units incorporated at 
these locations undergo reductive modification yielding a hydroxyl substituent at 
their β-position. The stereochemistries of the hydroxyl groups are dictated at the 
level of protein structure. The KR domain can attack the β-ketone from either 
side of the acyl chain, resulting in either a D- or L- configuration. The structure of 
the KR domain dictates the direction of substrate entry into the enzyme’s active 
site, which in turn determines the face of the keto-group that is presented for 
hydride transfer from NADPH (43). Module 4 of DEBS has a full compliment of 
reductive domains (KR, DH and ER). Extender units incorporated at this location 
undergo complete β–keto reduction, yielding an α/β alkane. By contrast, DEBS 
module 3 houses no functional reductive domains resulting in retention of the β–
keto group. Notably, however, this module does contain an oft unreported 
‘broken’ KR that controls epimerisation of the incorporated methylmalonyl 
extender unit, a function that was previously ascribed to this module’s KS 
domain (44, 45).  
To generate the fully functional DEBS PKS there is a requirement to assemble 
DEBS 1-3 into a single functional complex. This is facilitated by protein-protein 
interaction interfaces at the N- and C-termini of the individual DEBS 
polypeptides, which serve to link these three proteins together to form the intact 
megaenzyme. DEBS docking domains comprise complimentary N- and C-
terminal helical bundles of 30–50 and 80–130 residues respectively (46). 
Complex formation between complimentary docking domains is implicitly 
required to permit transfer of the growing product chain between neighboring 
modules that are housed on different polypeptides. 
Upon release from DEBS the cyclised 6-dEB macrolactone is subjected to post-
PKS tailoring, catalysed by a complement of stand-alone enzymes encoded 
within the ery gene cluster. 6-dEB is hydroxylated and glycosylated to form 
erythromycin D, which is then converted to erythromycin A through the action of 
the O-methyl transferase EryG and the hydroxylase EryK (47). Interestingly 
these two transformations occur in a sequence independent fashion, forming the 
isolatable intermediates erythromycin B and erythromycin C respectively. 
 
4. The Structural Enzymology of Modular PKSs 
Significant insights into the enzymology of PKS chain extension and processing 
have been provided by structural studies of isolated synthase domains. Crystal 
structures have been reported for AT, ACP, KS, KR, DH and ER domains amongst 
others, and NMR spectroscopy has been used extensively for the structural 
characterisation of ACPs (38, 48–51). These data have proven informative in 
establishing the roles and contributions of each domain during biosynthesis. 
Here we provide structural descriptions of the three core PKS domains (AT, ACP 
and KS), but direct readers to references (49, 50) for more comprehensive 
descriptions of PKS domain structure.  
Acyltransferases have been shown to possess a distinct two sub-domain 
architecture comprising a larger hydrolase like sub-domain fused to a smaller 
ferredoxin like sub-domain (52–55). The AT active site sits at the interface of the 
two sub-domains, at the base of a solvent exposed channel, and houses an 
invariant His-Ser catalytic dyad. ATs are proposed to employ a ping-pong bi-bi 
mechanism that proceeds via an acyl-enzyme intermediate. The intermediate is 
stabilised during catalysis by an oxyanion hole formed by backbone amides from 
neighboring amino acids within the enzyme active site. Resolution of the acyl-
enzyme intermediate occurs only in the presence of thiol nucleophiles rendering 
this intermediate sufficiently stable to permit its isolation and characterisation in 
vitro (56). The topology of the AT active site is in part dictated by amino acids 
that form defined substrate-selectivity motifs. Residues that occupy these 
positions play a role in dictating the specific acyl extender unit that the AT 
selects (57, 58). Substitution of these motifs has been used to alter AT selectivity 
giving rise to new natural products, though the universality of this approach 
remains questionable (59–61). Recently it has been proposed that extender unit 
selectivity is dictated more generally by a combination of structural features 
distributed throughout the enzyme fold (50). 
ACPs are small negatively charged helical bundles that provide a site of 
anchorage for acyl intermediates during biosynthesis (51, 62). The covalent 
attachment of intermediates to the ACP occurs via a post-translationally 
modified serine residue bearing a phosphopantetheine arm, which forms part of 
a conserved Asp-Ser-Leu motif. This motif is located at the N-terminus of helix 2 
of the protein, which is considered the key portion of the ACP for mediating 
interactions with each of its respective binding partners (63–65). In many 
instances ACPs exhibit a high degree of specificity for their cognate intra-module 
domains (63, 66). Undoubtedly this property is dictated by a combination of ACP 
sequence and the identity of the substrate or intermediate to which the ACP is 
tethered. Although originally considered as somewhat as a passive component of 
the biosynthetic machinery, it is becoming increasingly clear that ACPs play a 
more active role. This includes for example shielding of tethered acyl units to 
allow their presentation at appropriate time points or locations within their host 
module (67–69). 
Ketosynthase domains are dimeric proteins with a conserved thiolase fold (52, 
53, 70). Structurally KSs are comprised of two α-β-α-β-α protomers arranged in 
the form of a five-layered core, within which three layers of α-helices are 
separated by two layers of β-sheets. Although there is some structural 
divergence between KSs, they all exhibit a small number of universal features. 
These include retention of the overall fold described above, extensive and highly 
hydrophobic dimer interfaces, and a conserved active site cysteine that acts as a 
site for the covalent attachment of substrates and intermediates. Variations in KS 
structure are largely confined to the enzyme’s active site and associated regions, 
and have significant impact on substrate selectivity (52, 53, 71). Examples of this 
include the identity and location of the key catalytic active site residues 
(excluding the universally conserved Cys) and the steric and electrostatic 
topology of the active site and its associated solvent exposed access channel. 
Such variations influence the ability of KSs to act upon intermediates of different 
chain length, saturation state and stereochemistry, and inadvertently provide a 
proofreading or gate-keeping function (66, 72, 73). KS catalysed Claisen 
condensation can be achieved using either a Cys-His-His or Cys-His-Asn catalytic 
triad, along with an intermediate stabilising oxyanion hole.   
Despite continued progress in the structural characterisation of isolated PKS 
domains, 
it is only recently that structural techniques have been successfully applied to 
the study of intact PKS modules (74–77). These analyses have afforded a step-
change in the understanding of PKS enzymology and provided insight into the 
dynamic nature of chain extension and processing. Most significant amongst 
these studies has been the elucidation of the structure of module 5 from the 
pikromycin PKS (PikAIII) using cryo-electron microscopy (cryo-EM) (74, 75). 
Uniquely, in this study, a number of structures were determined in a range of 
states that mimic all stages of the module’s catalytic cycle. In addition, the 
resolution range within which these structures were obtained (7-11 Å) allowed 
the unambiguous placement of high resolution crystal structures and NMR 
models of domains homologous to those of PikAIII, yielding a series of pseudo-
atomic models describing the process of chain extension in its entirety. In an 
elegant series of experiments, PikAIII, which possesses a KS-AT-KR-ACP domain 
architecture, is shown to adopt a distinctive symmetrical arch-like structure 
comprising a single PikAIII homodimer. Dimerisation occurs via the KS domain, 
which sits at the top of the arch. The AT and KR domains from each monomer 
form descending struts, which together with the capping KS dimer form a single 
central reaction chamber accessible by the active sites of each of the KS, AT and 
KR domains that constitute the module (Fig. 4). The relative positions of each 
domain deviate significantly from those proposed in structural models of intact 
PKS modules. The location of the PikAIII module’s two ACPs are also resolved 
and are shown, using targeted chemical modifications designed to mimic a range 
of reaction cycle intermediates, to occupy distinct locations within the chamber 
during catalysis (Fig. 4). These include; a holo-ACP form bearing a 
phosphopantetheine arm, where the ACPs are located adjacent to their 
respective AT or KR domains (state 1); a form in which the ACPs carry a 
pentaketide intermediate, locating them next to their respective AT’s active sites 
(state 2); a form in which the ACPs are acylated with methylmalonate, and 
within which they occupy positions below their cognate KSs, primed for active 
site entry (state 3); a form within which the ACPs carries a β-ketohexaketide, 
mimicking the system following chain extension, where the ACPs locate next to 
their respective KRs ready for ketoreduction (state 4); and finally a form 
mimicking the culmination of the chain extension processes, where the ACPs, 
carrying β-hydroxyhexaketide groups, are  expelled from the PKS reaction 
chamber, facilitating chain transfer to the down-stream module (state 5). In each 
of the structures reported the two ACPs occupy equivalent positions on either 
side of the module dimer, suggesting that they operate in synchronous fashion. 
This is a likely consequence of space constraints within the reaction chamber 
and steric hindrance imposed by the down stream KS dimer. Analysis of the 
reported PikAIII cryo-EM structures also hints at dynamic motions in other 
domains within the PKS module and is a powerful illustration of the value of 
analysing the structures of individual proteins in the context of their interacting 
partners.  
 
5. Trans-AT Synthases: A New Paradigm in Modular PKS Enzymology 
A significant recent development in the study of PKSs was the identification of a 
second class of modular synthases whose domain and module architectures 
diverge significantly from those of the canonical DEBS like systems (78–80). This 
new family of modular PKSs, the trans-AT synthases, are notable for their highly 
mosaic structures that incorporate disparate biosynthetic features within a 
single megaenzyme complex (81). Trans-AT PKSs have been shown to have an 
evolutionary lineage distinct from that of the cis-AT DEBS like systems (46). 
Although trans-AT PKSs make use of the same step-wise sequential condensation 
chemistry employed by cis-AT synthases, they exploit a much broader repertoire 
of functional domains, make use of trans-acting elements to modify synthase 
intermediates, and exhibit module architectures that diverge from the classical 
KS-AT-ACP paradigm (46, 81, 82). Here we describe two examples of 
biosynthetic peculiarities common to trans-AT PKSs, but direct readers to more 
comprehensive reviews of this area (81, 82). 
The defining feature of trans-AT synthases is the absence of module embedded 
AT domains throughout the PKS. Substrate loading in these systems is instead 
provided in trans, by free-standing trans-acting ATs encoded for within the 
synthase gene cluster (83). Trans-acting ATs are found either as stand-alone 
enzymes, or as di- or tri- domain fusions proteins partnered with decarboxylases 
(DCs), ERs, and/or proof-reading acyl-hydrolases (AH; Fig. 5) (78, 84–86). The 
role of trans-ATs in substrate loading has been demonstrated both in vivo and in 
vitro, and initial structural and functional characterisation of these enzymes 
suggests that they possess the same general structure and catalytic mechanism 
as module embedded ATs, but are able to furnish multiple ACPs throughout the 
PKS complex with extender units (87–90). The mechanism of trans-AT 
recruitment to each extension module remains to be established, however, it has 
been suggested that there may be distinct acyltransferase docking domains 
located within trans-AT PKS modules that facilitate this process (91, 92).  
Another distinctive biosynthetic feature common to trans-AT PKSs is their use of 
a multi-protein hydroxymethylglutaryl CoA synthase (HCS) enzyme cassette to 
catalyse the introduction of methyl groups at β-carbon positions within product 
incorporated acyl extender units (93). To achieve this acetyl-ACP is condensed 
with the unreduced β-carbon of the nascent polyketide chain forming a β-
hydroxy-β-carboxymethyl intermediate. This intermediate is then subjected to 
sequential dehydration and decarboxylation to form the β-methyl group (Fig. 5) 
(89, 94–97). Structural studies of trans-AT PKS di-domain ACPs upon which β-
branching takes place have identified a distinct amino acid signature that 
appears to target the branching machinery to these locations. This discovery 
raises the intriguing possibility of implementing β-branching chemistry at a 
range of locations throughout PKSs, by introducing appropriate amino acid 
signatures into ACPs that do not, in their native state, support branch formation. 
 
6. Reengineering of PKS assembly lines 
The highly modular architectures of PKSs make these systems attractive targets 
for reengineering as a mechanism for accessing unnatural natural products with 
novel or enhanced functionality. This approach gains credence from the notion 
that polyketide scaffolds have been evolutionarily selected for optimum 
performance within their producer’s environmental niche, and as such they may 
be of limited utility in wider contexts. The targeted modification of polyketides 
through manipulation of the cellular machineries responsible for their 
biosynthesis may therefore yield derivatives of the parent compound with, for 
example, improved clinical efficacy. The tractability of PKS reengineering was 
initially demonstrated in DEBS (98). These investigations resulted in the 
establishment of a set of rules for the purposeful manipulation of modular 
synthases (98). Despite these initial successes, the reengineering of modular 
PKSs has however proved to be much more challenging than was initially 
anticipated. Though with recent advances in the delineation of synthase 
enzymology, the development of more robust experimental tools for targeted 
high-throughput genetic manipulation and DNA synthesis, and improvements in 
analytical techniques and computation, PKS reengineering appears poised for a 
renascence.  
A number of strategies have been proposed for the successful manipulation of 
PKSs. These focus on targeted modifications at the module, domain, or amino 
acid level, or involve the refactoring of precursor biosynthesis or post-PKS 
tailoring. Approaches targeted at the module level have focused on the deletion, 
insertion or substitution of intact modules within PKS complexes. This approach 
has been successfully applied to DEBS, where substitution of the loading module 
of DEBS 1 with that from the tylosin PKS resulted in a hybrid system selective 
solely for a propionate starter unit (99). Similarly, replacement of the DEBS 1 
starter module with that from the oleandomycin PKS yielded a hybrid system 
within which acetate was exclusively incorporated as the starter unit (99). 
Although pioneered in DEBS, loading module substitution has been successfully 
implemented in other systems. For example, replacement of the loading module 
initiating avermectin biosynthesis, which specifically incorporates isobutyryl-
CoA, with that of the cyclohexanecarboxylic (CHC) phoslactomycin PKS loading 
module from Streptomyces platensis, permitted the biosynthesis of the anti-
parasitic veterinary medicine doramectin (100). To achieve this outcome it was 
also necessary to express the five proteins responsible for the biosynthesis of the 
CHC-CoA precursor in tandem with the hybrid PKS. 
Targeted manipulation at the domain level requires less extensive interference 
with the PKS, however, the importance of intra-module protein-protein 
interactions should always be considered. The tolerance of DEBS to domain 
swapping has been probed extensively (101, 102). Each extension module within 
this PKS contains an AT domain selective for (2S)-methylmalonyl-CoA. 
Substitution of these domains with ATs selective for malonyl, ethylmalonyl, or 
methoxymalonyl extender units has permitted the biosynthesis of 
regioselectively modified polyketides with the expected chemical composition 
(102–106). Substitution of individual domains in DEBS modules 2, 5 and 6, with 
counterparts from the rapamycin PKS, possessing different substrate 
specificities and reductive capabilities, as well as the insertion of additional 
domains from the same system, has been used to produce an extensive range of 
6-dEB analogues (102, 107, 108).  
To minimise the deleterious effects of PKS reengineering, the targeted mutation 
of individual residues within modules or domains represents an attractive, less 
invasive approach. As the number of publically available genome sequences and 
protein structures increases exponentially, so increases the ability of researchers 
to make informed site-specific changes that confer or modulate protein function. 
This may include targeted changes that impact catalytic activity, substrate 
selectivity, co-factor binding, or stereoselectivity. Examples of the use of this 
approach in DEBS include deactivation of the enoyl reductase domain of module 
4 permitting the biosynthesis of Δ6,7-anhydroerythromycin C (109), and targeted 
alteration of the substrate selectivities of extender module AT domains to allow 
malonyl-CoA and fluoromalonyl-CoA to be accepted as substrates (110). This 
approach has been further informed by computational methods. For example the 
use of quantum mechanics/molecular mechanics (QM/MM) methods was 
instrumental in the design of a mutagenesis strategy to reengineer DEBS AT6 to 
accept a non-natural 2-propargylmalonyl extender unit (111). The polyketide 
biosynthesised by this modified PKS possesses a synthetically functionalisable 
handle that can be exploited to generate an even greater number of useful 
derivatives.  
In addition to reengineering strategies that focus explicitly on the PKS itself, 
complimentary approaches that target the allied starter and extender unit 
biosynthetic pathways, or focus on post synthase tailoring reactions have been 
investigated. The former have included the targeted mutation of acyl-CoA 
synthetases (112, 113), or the replacement of endogenous acyl-CoA pathways 
with those that generate alternative precursors (114). For the latter, many 
successful approaches have involved the repurposing of glycosyltransferases to 
generate polyketide products with altered glycosylation patterns and 
consequently more favourable toxicities, solubilities and bioavailabilities (115, 
116). 
 
7. Conclusions 
In recent years significant progress has been made in the genetic, chemical, 
biochemical and structural characterisation of modular PKSs and their 
constituent parts. Despite this, many questions still remain, and without doubt 
the study of modular synthases will remain a fertile area of research for many 
years to come. Studies of PKS structure and function are providing unexpected 
insights into the assembly, operation and dynamics of these systems, and the 
frequency with which new PKS gene clusters are being identified and annotated 
continues to rise exponentially.  
Notably, one area of modular PKS research that has progressed more slowly than 
was hoped is that of synthase reengineering. Methods developed to enable the 
rational redesign of modular PKSs and their products have proven non-trivial to 
implement successfully across multiple, often closely related systems, and 
consequently many approaches that showed initial promise have failed to 
deliver. That said, new fundamental insights into the enzymology of these 
systems will undoubtedly expedite the development of the necessary tools and 
technologies that are required for robust, broadly implementable synthase 
reengineering.  
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Figure legends 
Fig. 1. Illustrative examples of polyketide natural products and their respective 
bioactivities. 
 
Fig. 2. (a) Chemical structures of example PKS starter and extender units. (b) 
Individual steps involved in extender unit selection and chain incorporation. (c) 
Illustrative chain modifications catalysed by module embedded PKS domains. 
 
Fig. 3. Domain organisation of the 6-deoxyerythronolide B synthase (DEBS) and 
the biosynthetic route to erythromycin A. Domains are coloured based on their 
host module. Numbered arrows indicate the direction and order of product chain 
extension and transfer. 
 
Fig. 4. (a) Solid rendering of the cryo-EM map of holo PikAIII (EMD-5647). (b) 
Cartoon representation of holo PikAIII showing the relative position of each 
domain within the module. (c) Conformational states of PikAIII observed by 
cryo-EM (state 1 EMD-5647, state 2 EMD-5663, state 3 EMD-5653, state 4 EMD-
5664, state 5 EMD-5666). Each state equates to a defined step within the 
module’s catalytic cycle. The location of each PikAIII ACP is indicated by a yellow 
circle. In states 1 and 3 the ACPs occupy overlapping positions at the front and 
rear of the module. 
 
Fig 5. (a) Domain organisation within polypeptides that house trans-acting 
acyltransferases. (b) Scheme for the introduction of β-methyl branches in to 
polyketides via the HCS cassette route. Only the ACP domains of the modules that 
support the product chain are shown. ECH, enoyl CoA hydratase. 
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